High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Genome engineering of T lymphocytes, the main effectors of antitumor adaptive immune responses, has the potential to uncover unique insights into their functions and enable the development of next-generation adoptive T cell therapies. Viral gene delivery into T cells, which is currently used to generate CAR T cells, has limitations in regard to targeting precision, cargo flexibility, and reagent production. Nonviral methods for effective CRISPR/Cas9-mediated gene knock-out in primary human T cells have been developed, but complementary techniques for nonviral gene knock-in can be cumbersome and inefficient. Here, we report a convenient and scalable nonviral method that allows precise gene edits and transgene integration in primary human T cells, using plasmid donor DNA template and Cas9-RNP. This method is highly efficient for single and multiplex gene manipulation, without compromising T cell function, and is thus valuable for use in basic and translational research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous studies showing that overly high plasmid concentrations can lead to cellular toxicity, reduced transfection efficiency, or activation of cellular stress responses to impair HDR efficiency [20,25].”
From Rapid and Robust Generation of Homozygous Fluorescent Reporter Knock-In Cell Pools by CRISPR-Cas9 (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807 · cited 1×
“Gene set enrichment analysis (GSEA) was performed using R Bioconductor package enrichplot (Yu, 2021) andmsigdbr (Subramanian et al., 2005; Liberzon et al., 2015).”
MethodOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 2×
“This approach was used, for instance, to insert a CAR construct into the T cell receptor α constant (TRAC) region locus, which placed the CAR under the control of the endogenous TCR promotor, thus improving its performance (Eyquem et al., 2017).”
MethodLi, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715 · cited 1×
“Homology-directed repair (HDR) of double-strand DNA breaks introduced by targeted gene editing methods, such as transcription activator–like effector nucleases, zinc finger nucleases, or CRISPR/Cas9, can be used to make precise changes to a genomic sequence, including the insertion of long stretches of DNA at a define…”
BackgroundCRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · cited 2×
“As we and others have demonstrated, chromosomal translocations are a predicted byproduct of multiplex gene perturbation (Stadtmauer et al., 2020).”
BackgroundResultA bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J., Baird, M. A., Sell, B. R., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,289 · cited 1×
“, 2005) fused with the fluorescent protein mNeonGreen (mNG; Shaner et al., 2013).”
MethodChu, V. T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., & Kühn, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3198 · Cited by 1,210
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090 · cited 1×
“CRISPR-mediated gene knock-out using Cas9-ribonucleoprotein (RNP) delivery into primary human T cells represents a rapid and versatile approach for introducing genetic loss-of-function perturbations in this clinically relevant cell type (Schumann et al., 2015; Hendel et al., 2015; Seki and Rutz, 2018; Oh et al., 2019).”
MethodHockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R. C., Katibah, G. E., Amora, R., Boydston, E. A., Zeitler, B., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1562 · Cited by 1,056 · cited 1×
“Targeting of this site is not expected to induce adverse physiological effects upon disruption, and allows robust expression of exogenously inserted genes (Smith et al., 2008; Hockemeyer et al., 2009; Chu et al., 2015).”
BackgroundReprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839 · cited 19×
“Several protocols using AAV vectors, togetherwith Cas9 or Cas12a, were developed to introduce CARs or TCRs into the TRAC locus of T cells, often demonstrating ≥50% transgene integration through combined Cas9-RNP electroporation and virus infection (Mansilla-Soto et al., 2022; Zhang et al., 2021).”
BackgroundMethodInfluentialVakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782 · cited 2×
“Several studies have subsequently reported high editing efficiencies using AAV-based repair templates (Choi et al., 2019; Vakulskas et al., 2018; Dai et al., 2019).”
MethodGeneration of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702 · cited 1×
“CRISPR-mediated gene knock-out using Cas9-ribonucleoprotein (RNP) delivery into primary human T cells represents a rapid and versatile approach for introducing genetic loss-of-function perturbations in this clinically relevant cell type (Schumann et al., 2015; Hendel et al., 2015; Seki and Rutz, 2018; Oh et al., 2019).”
MethodClinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Discriminating self from non-self in nucleic acid sensing
Schlee, M., & Hartmann, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.78 · Cited by 593 · cited 1×
“Innate immune sensing (Schlee and Hartmann, 2016) of homology donor DNA and/or AAV capsids (Ronzitti et al.”
BackgroundZhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500 · cited 1×
“Transposon-based gene deliverymethods, such as the piggyBac and Sleeping Beauty systems, have been developed as nonviral alternatives (Monjezi et al., 2017; Kebriaei et al., 2016; Hudecek and Ivics, 2018).”
MethodEfficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · cited 1×
“Since plasmid DNA is toxic to T cells (Mandal et al., 2014; Su et al., 2016), the use of these small backbone vectors could help to reduce the amount of DNA needed for transfection.”
BackgroundThe TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses
Ward-Kavanagh, L. K., Lin, W. W., Šedý, J. R., & Ware, C. F. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.019 · Cited by 463
Directed evolution of human T-cell receptors with picomolar affinities by phage display
Li, Y., Moysey, R., Molloy, P. E., Vuidepot, A.-L., Mahon, T., Baston, E., Dunn, S., Liddy, N., Jacob, J., Jakobsen, B. K., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1070 · Cited by 442 · cited 1×
“We designed a donor template with 500-bp homology arms targeting exon 1 of the TRAC locus and encoding the α chain of the NY-ESO-1–specific 1G4 TCR (Li et al., 2005) fused with the fluorescent protein mNeonGreen (mNG; Shaner et al.”
MethodGray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
Modlich, U., Navarro, S., Zychlinski, D., Maetzig, T., Knoess, S., Brugman, M. H., Schambach, A., Charrier, S., Galy, A., Thrasher, A. J., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.179 · Cited by 387
Seki, A., & Rutz, S. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171626 · Cited by 372 · cited 3×
“CRISPR-mediated gene knock-out using Cas9-ribonucleoprotein (RNP) delivery into primary human T cells represents a rapid and versatile approach for introducing genetic loss-of-function perturbations in this clinically relevant cell type (Schumann et al., 2015; Hendel et al., 2015; Seki and Rutz, 2018; Oh et al., 2019).”
MethodSelf-citationHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · cited 1×
“Innate immune sensing (Schlee and Hartmann, 2016) of homology donor DNA and/or AAV capsids (Ronzitti et al., 2020), as well as a DNA damage response triggered by DNA break formation (Nambiar et al.”
BackgroundAdvances in Non-Viral DNA Vectors for Gene Therapy
Hardee, C., Arévalo-Soliz, L., Hornstein, B., & Zechiedrich, L. (2017) · Genes · doi:10.3390/genes8020065 · Cited by 356 · cited 1×
“, pUC57), several smaller circularized DNA backbones including minicircles, midges, and nanoplasmids have been described for cell engineering applications (Hardee et al., 2017).”
BackgroundOptimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning
Wang, D., Zhang, C., Wang, B., Li, B., Wang, Q., Liu, D., Wang, H., Zhou, Y., Shi, L., Lan, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12281-8 · Cited by 331 · cited 1×
“, 2016), and the DeepCas9 algorithm (Wang et al., 2019).”
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319 · cited 1×
“However, the use of AAV-based homology donors requires cumbersome and expensive virus production methods (Bak et al., 2018), which currently limits its broader application in the research community.”
BackgroundNguyen, D. N., Roth, T. L., Li, P. J., Chen, P. A., Apathy, R., Mamedov, M. R., Vo, L. T., Tobin, V. R., Goodman, D., Shifrut, E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0325-6 · Cited by 312
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 305 · cited 1×
“Since plasmid DNA is toxic to T cells (Mandal et al., 2014; Su et al., 2016), the use of these small backbone vectors could help to reduce the amount of DNA needed for transfection.”
BackgroundChoi, B. D., Yu, X., Castano, A. P., Darr, H., Henderson, D. B., Bouffard, A. A., Larson, R. C., Scarfò, I., Bailey, S. R., Gerhard, G. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0806-7 · Cited by 290 · cited 2×
“Several studies have subsequently reported high editing efficiencies using AAV-based repair templates (Choi et al., 2019; Vakulskas et al., 2018; Dai et al., 2019).”
MethodMonjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics, Z., & Hudecek, M. (2017) · Leukemia · doi:10.1038/leu.2016.180 · Cited by 258
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Smith, J. R., Maguire, S., Davis, L. A., Alexander, M., Yang, F., Chandran, S., ffrench-Constant, C., & Pedersen, R. A. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0039 · Cited by 241 · cited 1×
“Targeting of this site is not expected to induce adverse physiological effects upon disruption, and allows robust expression of exogenously inserted genes (Smith et al., 2008; Hockemeyer et al., 2009; Chu et al., 2015).”
BackgroundSather, B. D., Romano Ibarra, G. S., Sommer, K., Curinga, G., Hale, M., Khan, I. F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5530 · Cited by 223
CRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 208 · cited 1×
“, 2020), as well as a DNA damage response triggered by DNA break formation (Nambiar et al., 2022), could stress the modified T cell population.”
BackgroundPaired analysis of TCRα and TCRβ chains at the single-cell level in mice
Dash, P., McClaren, J. L., Oguin, T. H., Rothwell, W., Todd, B., Morris, M. Y., Becksfort, J., Reynolds, C., Brown, S. A., Doherty, P. C., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44752 · Cited by 198
HLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
Schober, K., Müller, T. R., Gökmen, F., Grassmann, S., Effenberger, M., Poltorak, M., Stemberger, C., Schumann, K., Roth, T. L., Marson, A., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0409-0 · Cited by 178 · cited 8×
“To this end, we harvested T cells engineered to express either the NY-ESO-1– reactive 1G4 TCR or CMV A2/pp65495–503 TCR6-2 on day 8 of culture.”
BackgroundInfluentialAsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
Zhang, L., Zuris, J. A., Viswanathan, R., Edelstein, J. N., Turk, R., Thommandru, B., Rube, H. T., Glenn, S. E., Collingwood, M. A., Bode, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24017-8 · Cited by 162 · cited 1×
“Several protocols using AAV vectors, togetherwith Cas9 or Cas12a, were developed to introduce CARs or TCRs into the TRAC locus of T cells, often demonstrating ≥50% transgene integration through combined Cas9-RNP electroporation and virus infection (Mansilla-Soto et al., 2022; Zhang et al., 2021).”
MethodOne-step generation of modular CAR-T cells with AAV–Cpf1
Dai, X., Park, J. J., Du, Y., Kim, H. R., Wang, G., Errami, Y., & Chen, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0329-7 · Cited by 160
Redmond, D., Poran, A., & Elemento, O. (2016) · Genome Medicine · doi:10.1186/s13073-016-0335-7 · Cited by 139
Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1121 · Cited by 128 · cited 1×
“Viral vectors, in particular adeno-associated viruses (AAV), have been used to deliver donor DNA templates for HDRmediated target gene knock-in in T cells (Sather et al., 2015; Wang et al., 2016; Eyquem et al., 2017; Choi et al., 2019).”
MethodThemis sets the signal threshold for positive and negative selection in T-cell development
Fu, G., Casas, J., Rigaud, S., Rybakin, V., Lambolez, F., Brzostek, J., Hoerter, J. A. H., Paster, W., Acuto, O., Cheroutre, H., et al. (2013) · Nature · doi:10.1038/nature12718 · Cited by 128 · cited 1×
“with the full-length 1G4 TCR at 4 kb (TRAC_NotchICD_1G4), and the gene encoding Themis, which plays a regulatory role in both positive and negative T cell selection during late thymocyte development (Fu et al., 2013), as a P2A-in-frame fusion with the full length 1G4 TCR at 5.”
A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells
Bloemberg, D., Nguyen, T., MacLean, S., Zafer, A., Gadoury, C., Gurnani, K., Chattopadhyay, A., Ash, J., Lippens, J., Harcus, D., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.012 · Cited by 119
Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system
Luke, J., Carnes, A. E., Hodgson, C. P., & Williams, J. A. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.017 · Cited by 114
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
Singh, N., Shi, J., June, C. H., & Ruella, M. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0417-7 · Cited by 85 · cited 1×
“Homology-directed repair (HDR) of double-strand DNA breaks introduced by targeted gene editing methods, such as transcription activator–like effector nucleases, zinc finger nucleases, or CRISPR/Cas9, can be used to make precise changes to a genomic sequence, including the insertion of long stretches of DNA at a define…”
BackgroundDual TCR T Cells: Identity Crisis or Multitaskers?
Schuldt, N. J., & Binstadt, B. A. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800904 · Cited by 72
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Hudecek, M., & Ivics, Z. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.003 · Cited by 64 · cited 1×
“Transposon-based gene deliverymethods, such as the piggyBac and Sleeping Beauty systems, have been developed as nonviral alternatives (Monjezi et al., 2017; Kebriaei et al., 2016; Hudecek and Ivics, 2018).”
MethodCRISPR-Based Tools in Immunity
Simeonov, D. R., & Marson, A. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041522 · Cited by 63 · cited 1×
“Emerging approaches that use DNA nuclease technologies have enabled mutant gene correction, the introduction of entire genes or gene fusions into a desired location, or the manipulation of regulatory elements, none of which are possible with existing retro- or lentivirus–based methodology (Simeonov and Marson, 2019).”
BackgroundExtracellular Lactate: A Novel Measure of T Cell Proliferation
Grist, J. T., Jarvis, L. B., Georgieva, Z., Thompson, S., Kaur Sandhu, H., Burling, K., Clarke, A., Jackson, S., Wills, M., Gallagher, F. A., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700886 · Cited by 59 · cited 1×
“Extracellular lactate levels were analyzed as a surrogate for cell proliferation (Grist et al., 2018) using the Lactate-Glo Assay (Promega) according to the manufacturer’s protocol.”
MethodRibonucleoprotein Transfection for CRISPR/Cas9‐Mediated Gene Knockout in Primary T Cells
Oh, S. A., Seki, A., & Rutz, S. (2018) · Current Protocols in Immunology · doi:10.1002/cpim.69 · Cited by 54 · cited 2×
“CRISPR-mediated gene knock-out using Cas9-ribonucleoprotein (RNP) delivery into primary human T cells represents a rapid and versatile approach for introducing genetic loss-of-function perturbations in this clinically relevant cell type (Schumann et al., 2015; Hendel et al., 2015; Seki and Rutz, 2018; Oh et al., 2019).”
MethodSelf-citationpDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids
Williams, J. A., Luke, J. M., Johnson, L., & Hodgson, C. P. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.033 · Cited by 37
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 31 · cited 1×
“However, production and purification of AAV not only represents a significant clinical manufacturing challenge (Loo and van derWright, 2016; Halbert et al., 2018; Davidsson et al., 2020), it also limits more widespread use of this approach in the research community.”
BackgroundAAV6 Vector Production and Purification for Muscle Gene Therapy
Halbert, C. L., Allen, J. M., & Chamberlain, J. S. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3_18 · Cited by 28
Duchenne Muscular Dystrophy: Methods and Protocols
Tucciarone, L., Etxaniz, U., Sandonà, M., Consalvi, S., Puri, P., & Saccone, V. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7374-3 · Cited by 8 · cited 1×
“However, production and purification of AAV not only represents a significant clinical manufacturing challenge (Loo and van derWright, 2016; Halbert et al., 2018; Davidsson et al., 2020), it also limits more widespread use of this approach in the research community.”
Background
Cited by
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2023) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 285
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 154
“Process improvements, including single-stranded DNA donor templates 62,71 , nanoplasmids 72 , intranuclear template shuttling 73 , Cas9 RNP stabilization 73 and small molecule cocktails 71 , may increase editing rates.”
BackgroundLei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 175
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“Targeted insertion of a transgene into the host genome can be mediated by HDR following double-strand break introduced by CRISPR at a specific genomic site (Hayashi et al., 2020; Nitzahn et al., 2021; Oh et al., 2022).”
Background
Metadata
- Authors
- Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S.
- Affiliations
- Genentech (US)
- Corresponding author
- Rutz, Sascha
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2022-04-22
- Volume
- 219
- Issue
- 5
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC9040063
- OpenAlex
- W4224255508
- Cited by
- 88
- References
- 59
- Citations by year
- 2026: 19 · 2025: 19 · 2024: 23 · 2023: 21 · 2022: 5
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR/Cas9, human T cells, gene knock-in, gene knockout, transgene integration, Cas9 ribonucleoprotein, multiplex genome editing, adoptive T cell therapy, T cell engineering
- MeSH terms
- Gene Editing, DNA, Humans, Plasmids, T-Lymphocytes, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.